lysis syndrome. A dose-ranging phase I trial is expected to begin during fourth quarter 2009. EnzymeRx also plans to resume clinical trials of intramuscular uricase-PEG20 as a therapy for gout.

Uricase-PEG 20, a recombinant uricase derived from Candida utilis covalently attached to PEG (polyethylene glycol) of 20 kDa, is designed to reduce the antigenicity of uricase and prolong its half-life.

## cystic fibrosis/hypertension therapies, DiscoveryBiomed

### DiscoveryBiomed awarded SBIR Phase 2 grant by NIH

DiscoveryBiomed announced on 28 September 2009 that it has received a US$750 000 Small Business Innovations Research (SBIR) Phase 2 grant from the National Institutes of Health (NIH;USA). The grant will be used to further the research into the discovery and development of small molecules for the treatment of cystic fibrosis, hypertension and chronic kidney diseases with hypertension. The program, which employs the company's electrical high-throughput screening friendly method, focuses on an epithelial sodium channel that is the rate-limiting step for salt management in the distal portions of the kidney and in the respiratory tract; an overactive sodium channel leads to dehydration of the airways and high salt blood concentrations (resulting in hypertension). Discovery stage research is ongoing in the USA and lead compounds will be tested in preclinical studies in collaboration with the University of Alabama at Birmingham (USA) and Johns Hopkins University School of Medicine (USA).

# Conferences

# EuroBiO 2009, 23-25 September 2009, Lille, France

# Opportunities with TFChem

## cancer therapy, TFChem

### TFChem licensing offer, Worldwide

At EuroBiO 2009, 23-25 September 2009, Lille, France, R&D Focus was informed by Geraldine Deliencourt-Godefroy, CEO at TFChem, that the company's glycoconjugates for the potential treatment of cancer are available for licensing, worldwide. The glycoconjugates are being developed with TFChem's proprietary GlycoMim technology platform, which utilizes fluorination to increase the bioavailability, stability and efficacy of sugars. Discovery stage research is ongoing in France.

For further information on the licensing opportunities available, contact:

Geraldine Deliencourt-Godefroy
CEO
TFChem
Voie de l'innovation
Pharma Parc II
Chaussee du Vexin
27100 Val de Reuil
France

Tel: +33 2 32 09 01 16
Fax: +33 2 32 25 07 64
Email: geraldine.deliencourt@tfchemistry.com

## vaccine, cancer, TFChem

### TFChem licensing offer, Worldwide

TFChem is utilizing its proprietary GlycoMim technology for the development of antigens with potential in the development of vaccines for the treatment or prevention of cancer. The GlycoMim technology replaces oxygen atoms contained in sugars with fluorinated functions to increase their stability, bioavailability and efficacy. Discovery stage research is under way in France. At EuroBiO 2009, 23-25 September 2009, Lille, France, Geraldine Deliencourt-Godefroy, CEO at TFChem, informed R&D Focus that this discovery program is available for licensing worldwide.

For further information on the licensing opportunities available, contact:

Geraldine Deliencourt-Godefroy
CEO
TFChem
Voie de l'innovation
Pharma Parc II
Chaussee du Vexin
27100 Val de Reuil
France

Tel: +33 2 32 09 01 16
Fax: +33 2 32 25 07 64
Email: geraldine.deliencourt@tfchemistry.com

## vaccine, HIV infection, TFChem

### TFChem licensing offer, Worldwide

At EuroBiO 2009, 23-25 September 2009, Lille, France, Geraldine Deliencourt-Godefroy, CEO at TFChem, informed R&D Focus that its discovery stage program for the development of antigens with potential in the development of HIV vaccines is available worldwide for licensing. The antigens are under development using TFChem's proprietary GlycoMim technology, which replaces oxygen atoms contained in sugars with fluorinated functions to increase their stability, bioavailability and efficacy.

For further information on the licensing opportunities available, contact:

Geraldine Deliencourt-Godefroy
CEO
TFChem
Voie de l'innovation
Pharma Parc II
Chaussee du Vexin
27100 Val de Reuil
France

Tel: +33 2 32 09 01 16
Fax: +33 2 32 25 07 64
Email: geraldine.deliencourt@tfchemistry.com

## inflammatory disease therapy, TFChem

### TFChem licensing offer, Worldwide

TFChem is seeking to out-license its discovery stage program for the development of agents for the treatment of inflammatory diseases, R&D Focus was told at EuroBiO 2009, 23-25 September 2009, Lille, France, by Geraldine Deliencourt-Godefroy, CEO at TFChem. The agents are under development using TFChem's proprietary GlycoMim technology, which replaces oxygen atoms contained in sugars with fluorinated functions to increase their stability, bioavailability and efficacy.

For further information on the licensing opportunities available, contact:

Geraldine Deliencourt-Godefroy
CEO
TFChem
Voie de l'innovation
Pharma Parc II
Chaussee du Vexin
27100 Val de Reuil
France

Tel: +33 2 32 09 01 16
Fax: +33 2 32 25 07 64
Email: geraldine.deliencourt@tfchemistry.com

## opioid glycopeptides, TFChem

### TFChem licensing offer, Worldwide

TFChem is developing glycopeptides that act on the delta opioid receptor for the potential treatment of pain. The opioid glycopeptides are being developed using TFChem's proprietary GlycoMim technology. The GlycoMim technology has utility in the development of glycomimetics in which oxygen atoms contained in sugars are replaced with fluorinated functions, leading to increased stability, bioavailability and efficacy. At EuroBiO 2009, R&D Focus was informed by Geraldine Deliencourt-Godefroy, CEO at TFChem, that the glycopeptides are available for licensing, worldwide.

For further information on the licensing opportunities available, contact:

Geraldine Deliencourt-Godefroy
CEO
TFChem
Voie de l'innovation
Pharma Parc II
Chaussee du Vexin
27100 Val de Reuil
France

Tel: +33 2 32 09 01 16
Fax: +33 2 32 25 07 64
Email: geraldine.deliencourt@tfchemistry.com

## GlycoMim

### TFChem partnering opportunity, Worldwide

Geraldine Deliencourt-Godefroy, CEO at TFChem, informed R&D Focus at EuroBiO 2009, 23-25 September 2009, Lille, France, that TFChem is seeking partners for the development of fluorinated glycomimetics utilizing its proprietary

GlycoMim technology. The GlycoMim technology replaces oxygen atoms contained in sugars with fluorinated functions to increase their stability, bioavailability and efficacy. It may be applied to the development of analogues of existing glycoconjugates, neoglycosylation of active molecules, and new fluoroglycosylated chemical entities.

For further information on the partnering opportunities available, contact:

Geraldine Deliencourt-Godefroy
CEO
TFChem
Voie de l'innovation
Pharma Parc II
Chaussee du Vexin
27100 Val de Reuil
France

Tel: +33 2 32 09 01 16
Fax: +33 2 32 25 07 64
Email: geraldine.deliencourt@tfchemistry.com

## SGLT inhibitors, Sirona Biochem

### TFChem preclinical evaluation, Canada

A lead candidate sodium glucose transporter (SGLT) inhibitor from the collaboration program between TFChem and Sirona Biochem has been selected, R&D Focus was informed at EuroBiO 2009, 23-25 September 2009, Lille, France, by Geraldine Deliencourt-Godefroy, CEO at TFChem. Preclinical studies with the lead candidate have initiated. The SGLT inhibitor is under development for the treatment of diabetes and obesity. It was developed under an agreement signed in September 2008; TFChem utilized its GlycoMim technology for the design and synthesis of SGLT inhibitors.

## 49th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), 12-15 September 2009, San Francisco, USA

## CYT 107

### Cytheris clinical data (HIV infection)

At the 49th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), 12-15 September 2009, San Francisco, USA, Cytheris presented data from an interim analysis of a randomized, placebo-controlled, single-blind, dose-escalation phase I/IIa trial (CLI-107-06;INSPIRE) of CYT 107 in chronically infected HIV patients with a CD4 T-lymphocyte count of 101-400 cells/mm$^3$ and plasma HIV RNA less than 50 copies mL after receiving highly active antiretroviral therapy (HAART) for 12 months prior to the trial. Patients in the trial received three weekly sc injections of 10, 20 or 30 mcg/kg CYT 107 or placebo. A 152% and a 87% increase over baseline CD4 counts at day 28 and 12 weeks, respectively, following administration of CYT 107 10 mcg/kg/week for three weeks (p=0.006) was observed. CD8 cell counts in the 10 mcg/kg/week group increased by 91% and 42% compared with baseline at day 28 and week 12, respectively (p=0.006). In the 20 mcg/kg/week group increases in CD4 count of 205% and 135% were observed at day 28 and week 12, respectively, compared with baseline. CD8 counts in the 20 mcg/kg/week group increased by 131% and 65% at day 28 and week 12, respectively, compared with baseline. One of seven patients in the 10 mcg/kg/week group and five of eight patients in the 20 mcg/kg/week group experienced CD4 counts greater than 500 cells/mm$^3$ at week 12 (p less than 0.005). No clinical or laboratory side effects greater than grade 2 were observed.

CYT 107 is a recombinant human interleukin-7 (rIL-7), under development for the potential therapy of cancer and hepatitis C virus (HCV) infection as well as for the treatment of immunocompromised patients, including patients undergoing cancer treatment, recovering from bone marrow transplant, and HIV-infected patients. Phase I/IIa trials in HCV-infected patients and patients with melanoma and renal cancer are also ongoing.

## LTX 109

### Lytix Biopharma preclinical data

At the 49th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), 12-15 September 2009, San Francisco, USA, Lytix Biopharma reported preclinical data for LTX 109 (LYTIXAR), a broad-spectrum antimicrobial agent being developed for the topical treatment of bacterial skin infections. Lytix Biopharma began a randomized, double-blind phase I trial of LTX 109 in 30 volunteers in August 2009. In preclinical studies, LTX 109 showed good activity against staphylococci and streptococci and was also active against Gram negative bacteria and fungi. The agent showed in vivo efficacy in a murine skin infection model. In